Outpatient Prescription IssuesNCT06222424
Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues
A study testing outpatient prescription issues in people with Outpatient Prescription Issues, run by Methodist Health System at 1 site in United States.
Trial summary
The study aims to document the utility of Methodist Charlton Medical Center (MCMC's)Emergency Medicine Pharmacist (EMP) Collaborative Practice Agreement (CPA )utilization for the resolution of outpatient prescription issues. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Outpatient Prescription Issues
- What is being tested?
- outpatient prescription issues
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 350 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Dec 2023to 15 Mar 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023 and a progress note and documenting the reason for the call and action taken by the EMP.
Who cannot join
- CPA actions were misclassified as discharge prescription issue resolutions.
- Patients with prescriptions pursuant to late culture review, formulation changes not requiring a new prescription, prescription transfers to another pharmacy, or simple retransmission of prescriptions.
- Patients documented to have left the ED against medical advice.
Trial locations and contacts
1 site in 1 country.
United States1 site
Clinical Research Institute at Methodist Health System
Dallas, Texas, 75203
About this study
Official title: Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues: A Descriptive Study
The study aims to document the utility of Methodist Charlton Medical Center (MCMC's)Emergency Medicine Pharmacist (EMP) Collaborative Practice Agreement (CPA )utilization for the resolution of outpatient prescription issues. Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.
Read the detailed description
Use of an EMP CPA, which allows for broad prescriptive authority, will assist Emergency Department (ED )workflow by preventing a significant volume of new prescriptions needing to be sent by physician and mid-level providers. Will improve rates of ED re-visits. In addition, this Collaborative Practice Agreement (CPA) will not be associated with a large volume of new prescription errors.
- Conditions
- Outpatient Prescription Issues
- Being tested
- outpatient prescription issues
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
outpatient prescription issuesOther
Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
| Study group | Role | What they receive |
|---|---|---|
| Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023 | Other | Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge. Receives: Other: outpatient prescription issues |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of prescriptions and medication types sent to outpatient pharmacies
Number of prescriptions and medication types sent to outpatient pharmacies by EMPs pursuant to outpatient prescription issue resolution.
Measured: 2 years
Secondary outcomes (1)
Number of patients returning with complaint or diagnosis related to EMP generated prescriptions
Proportion of patients returning with a complaint or diagnosis related to index EMP-generated prescriptions at three and six-month time points
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2024
- Study start15 Dec 2023
- Primary completion1 Mar 2026
- Study completion15 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Outpatient Prescription IssuesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 350 participants (actual)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kevin Burnham, Pharm.D., Principal investigator, Methodist Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06222424
- Sponsor's protocol ID
- 045.PHA.2023.C
- Status last verified
- Jan 2026
- First submitted
- 16 Jan 2024
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No